Medical News / From ESC 2023: Bempedoic Acid Proves Cardiovascular Benefit Across Glycemic Spectrum in New Analysis

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful in the treatment algorithms for statin-intolerant patients with diabetes mellitus. Results of the study, which were presented at the European Society of Cardiology (ESC) Congress 2023, indicate use of bempedoic acid significantly reduced cardiovascular risk as a monotherapy, with the greatest absolute benefit observed in patients with diabetes and no adverse effect on glycemic measures observed. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more
Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more
For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more
For endocrinologists and the diabetes care team, GLP-1 receptor agonists have been a familiar face for ... read more